Sandoz Group Ltd Sponsored ADR (SDZNY) AI Stock Analysis

Sandoz Group Ltd Sponsored ADR

(Other OTC:SDZNY)

Select Model

Rating:66Neutral

Price Target:$108.00▲(7.90% Upside)

Action:downgraded

Date:08/05/26

Solid financial performance and positive earnings call sentiment drive the score, tempered by mixed technical indicators and high valuation; recent cash flow improvements and biosimilar momentum are key strengths.

Positive Factors

Biosimilar Growth and PipelineBiosimilars are becoming a larger growth engine, with 20% H1 growth and 33% of sales, while a 36-asset pipeline and multiple approvals expand future launch opportunities. This supports portfolio diversification and a durable position in a growing off-patent biologics market.

Negative Factors

Pricing ErosionManagement now expects mid-single-digit pricing declines in 2026, revised higher than its prior view, with Germany and North America cited as drivers. Persistent erosion can offset volume and biosimilar growth, limiting revenue quality and putting pressure on the margin trajectory.

Sandoz Group Ltd Sponsored ADR (SDZNY) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $43.03B
Dividend Yield: 1.02%
Average Volume (3M): 19.32K
Price to Earnings (P/E): 67.0
Beta (1Y): 0.69
Revenue Growth: 9.56%
EPS Growth: 180.05%
Country: US
Employees: 23,000
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Sandoz Group Ltd Sponsored ADR Business Overview & Revenue Model

Company Description

Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare...

Sandoz Group Ltd Sponsored ADR Earnings Call Summary

Earnings Call Date:Aug 04, 2026(Q2-2026)|% Change Since:25.99%|Next Earnings Date:Mar 12, 2024

Earnings Call SentimentPositive

The call presented a broadly positive performance story: strong biosimilar-led top-line growth, margin expansion, resilient cash generation despite a significant CapEx cycle, an enlarged 36-asset biosimilar pipeline, major product launches with leading market shares, and strategic investments (Ljubljana center) that support medium-term growth. Near-term challenges include increased pricing erosion (now expected mid-single-digit), temporary generics headwinds (notably in Q1 and in some international markets), short-term tender/pricing disruption in Germany, elevated one-off and settlement-related cash outflows, and a heavier CapEx profile in 2026. Management reaffirmed 2026 guidance and emphasized confidence in 2027–2028 growth driven by upcoming launches and the multisource GLP-1 strategy. On balance, the positives around revenue momentum, profitability improvement, pipeline breadth, and strong commercial execution outweigh the near-term operational and pricing headwinds.

Positive Updates

Top-line Growth

Net sales increased 5% in H1 (10% in USD) to USD 5.8bn with accelerating momentum into Q2 (+7% overall; North America +15% H1, +18% Q2).

Negative Updates

Generics Headwinds

Generics experienced a modest decline in H1 due to temporary headwinds (notably adverse anti-infectives B2B dynamics in Q1); generics only returned to low single-digit growth in Q2.

Company Guidance

Management confirmed 2026 guidance: net sales are expected to increase mid‑ to high‑single‑digit at constant currencies (H1 sales were USD 5.8bn, +5% cc), core EBITDA margin is targeted to expand by around 100 basis points (H1 margin 20.9%, +90bps Y/Y), and overall pricing is now expected to decline by a mid‑single‑digit percentage in 2026 (revised from a prior low‑to‑mid‑single‑digit view). They now assume a ~2 percentage‑point FX tailwind to net sales for the year (previously ~4pp) and still do not expect material FX impact on the core EBITDA margin; CapEx is expected to peak this cycle at ~USD 1.1bn (H1 CapEx ≈ USD 500m) while management free cash flow remained around USD 500m in H1, one‑off costs are expected at ~USD 0.3bn for the year, and the balance sheet targets include net debt/EBITDA below 2x (net debt ≈ USD 3.5bn, net‑debt-to-core‑EBITDA 1.4x, gross debt USD 5.9bn, liquidity USD 2.3bn, average borrowing cost <4%).

Sandoz Group Ltd Sponsored ADR Financial Statement Overview

Summary

Balanced financial profile with strong cash flow generation and stable balance sheet, offset by inconsistent profitability and revenue growth.

Income Statement

65Positive

Balance Sheet

70Positive

Cash Flow

75Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	11.62B	11.15B	10.38B	11.66B	9.30B	9.62B
Gross Profit	5.52B	5.24B	4.93B	5.33B	4.38B	4.54B
EBITDA	2.48B	2.26B	742.00M	1.00B	1.73B	1.87B
Net Income	645.84M	919.12M	1.00M	89.99M	847.75M	907.82M
Balance Sheet
Total Assets	22.79B	22.03B	19.91B	22.71B	17.55B	17.48B
Cash, Cash Equivalents and Short-Term Investments	1.25B	1.74B	1.19B	1.30B	80.01M	39.86M
Total Debt	6.20B	5.68B	4.85B	5.32B	4.18B	4.93B
Total Liabilities	13.79B	12.65B	11.74B	12.59B	8.80B	9.35B
Stockholders Equity	9.00B	9.38B	8.16B	10.10B	83.41K	8.12B
Cash Flow
Free Cash Flow	1.22B	810.00M	60.00M	-307.36M	821.99M	935.82M
Operating Cash Flow	1.72B	1.59B	656.00M	423.06M	1.22B	1.35B
Investing Cash Flow	-2.06B	-980.00M	-740.00M	-717.57M	-464.93M	-690.87M
Financing Cash Flow	159.95M	-197.00M	242.00M	1.45B	-831.47M	-656.87M

Sandoz Group Ltd Sponsored ADR Technical Analysis

Technical Analysis SentimentPositive

Last Price100.09

Price Trends

50DMA87.73Positive

100DMA86.45Positive

200DMA83.96Positive

Market Momentum

MACD3.85Negative

RSI69.65Neutral

STOCH80.39Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SDZNY, the sentiment is Positive. The current price of 100.09 is above the 20-day moving average (MA) of 91.73, above the 50-day MA of 87.73, and above the 200-day MA of 83.96, indicating a bullish trend. The MACD of 3.85 indicates Negative momentum. The RSI at 69.65 is Neutral, neither overbought nor oversold. The STOCH value of 80.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SDZNY.

Sandoz Group Ltd Sponsored ADR Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SDZNY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KNSA	80Outperform	$7.25B	64.50	17.27%	―	58.19%	192.34%
LQDA	72Outperform	$4.03B	28.72	149.64%	―	2233.65%	―
SDZNY	66Neutral	$43.95B	67.02	7.04%	1.02%	9.56%	180.05%
CORT	56Neutral	$8.77B	156.00	8.37%	―	16.02%	-59.24%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BFRI	49Neutral	$12.96M	-1.45	-127.78%	―	17.83%	73.13%
SCYX	47Neutral	$37.51M	-2.05	-21.10%	―	489.78%	45.39%

* Healthcare Sector Average

Performance Comparison

SDZNY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SDZNY	Sandoz Group Ltd Sponsored ADR	100.09	32.04	47.08%
CORT	Corcept Therapeutics	81.12	6.95	9.37%
SCYX	SCYNEXIS Inc	3.77	-1.34	-26.21%
KNSA	Kiniksa Pharmaceuticals Ltd. Class A	92.24	54.77	146.17%
LQDA	Liquidia Technologies	45.06	19.84	78.67%
BFRI	Biofrontera, Inc.	0.87	-0.23	-20.73%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 05, 2026

Sandoz Group Ltd Sponsored ADR AI Stock Analysis